VEXTF (Vext Science) EBIT: $-7.76 Mil (TTM As of Mar. 2026)

What is Vext Science EBIT?

Vext Science VEXTF -3.15% 69 EBIT is $-7.76 Mil as of Mar. 2026. GuruFocus rates VEXTF with a GF Score™ of 69/100 and a GF Value™ of $1.06 (Possible Value Trap). The stock has 3 warning signs investors should review.

Vext Science's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $0.20 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-7.76 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vext Science's annualized ROC % for the quarter that ended in Mar. 2026 was 0.00%. Vext Science's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.12%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vext Science's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -11.04%.

Vext Science (OTCPK:VEXTF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vext Science's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	0 * ( 1 - 0% )	/	( (112.141	+	108.552)	/ 2 )
=	0	/	110.3465
=	0.00 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	120.529	-	20.098	-	( 5.083	-	max(0, 28.494	-	16.784	+	5.083	))
=	112.141

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	117.179	-	18.947	-	( 5.542	-	max(0, 27.325	-	17.005	+	5.542	))
=	108.552

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Vext Science's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	0.8	/	( ( (38.552 + max(-9.739, 0))	+	(36.949 + max(-8.922, 0)) )	/	2 )
=	0.8	/	( ( 38.552	+	36.949 )	/	2 )
=	0.8	/	37.7505
=	2.12 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.231	+	7.467	+	1.661)	-	(20.098	+	0	+	0)
=	-9.739

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.269	+	8.574	+	1.182)	-	(18.947	+	0	+	0)
=	-8.922

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vext Science's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-7.757	/	70.285
	=	-11.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vext Science EBIT Related Terms

Vext Science EBIT Historical Data

* Premium members only.

The historical data trend for Vext Science's EBIT can be seen below:

Vext Science EBIT Chart

Vext Science Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

9.05

8.75

7.17

-17.20

-10.74

Vext Science Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-2.62	1.20	-2.14	-7.02	0.20

VEXTF vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vext Science EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vext Science's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vext Science's EV-to-EBIT falls into.

Save Embed

69GF Score

Vext Science Inc VEXTF

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Vext Science EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.76 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-7.76 Mil mean?

Vext Science (VEXTF) has a EBIT of $-7.76 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vext Science.

Is Vext Science's EBIT too high?

Vext Science's current EBIT is $-7.76 Mil. Overall, Vext Science has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Vext Science's EBIT compare to ZTS and UTHR?

Vext Science's EBIT of $-7.76 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Drug Manufacturers company?

A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vext Science. Vext Science's current EBIT is $-7.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vext Science stock overvalued right now?

Based on GuruFocus' analysis, Vext Science (VEXTF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.06, compared to a current price of $0.18 — trading 83.2% below its estimated fair value. The current EBIT is $-7.76 Mil. Vext Science's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Vext Science (VEXTF), the current EBIT is $-7.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vext Science (VEXTF) Overvalued in 2026?

Based on GuruFocus' analysis, Vext Science stock appears to be undervalued. The current stock price of $0.18 is trading 83.2% below its estimated GF Value™ of $1.06. GuruFocus considers Vext Science to be Possible Value Trap.

Key valuation signals for VEXTF:

EBIT: $-7.76 Mil
GF Value™: $1.06 vs. price of $0.18 (83.2% below fair value)
GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the VEXTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vext Science Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XCNQ:PLTH XCNQ:LEEF TSXV:DB XCNQ:BNXT XCNQ:CXXI TSXV:ZYUS TSXV:LSL XCNQ:IAN XCNQ:OPTI TSXV:ROMJ XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges VEXT:Canada

Address 4152 N. 39th Avenue, Admin, Phoenix, AZ, USA, 85019

Website https://www.vextscience.com

Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.

69GF Score

Get the complete analysis for VEXTF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18

Price

$1.06

GF Value

View VEXTF Analysis

See EBIT data for all stocks →